EWCZ vs REGN vs BIIB vs FAT vs VRTX

For growth investors, FAT Brands Inc.

(FAT) is the stronger pick with 23. 4% revenue growth year-over-year, versus -1. 9% for European Wax Center, Inc. (EWCZ). Regeneron Pharmaceuticals, Inc. (REGN) offers the better valuation at 17. 1x trailing P/E (15. 3x forward), making it the more compelling value choice. Analysts rate Regeneron Pharmaceuticals, Inc. (REGN) a "Buy" — based on 48 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Regeneron Pharmaceuticals, Inc.

(REGN) is the cheapest at 17. 1x versus Vertex Pharmaceuticals Incorporated at 27. 7x. On forward P/E, European Wax Center, Inc. is actually cheaper at 8. 5x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Regeneron Pharmaceuticals, Inc. wins at 2. 43x versus Vertex Pharmaceuticals Incorporated's 2. 69x.

Over the past 5 years, Vertex Pharmaceuticals Incorporated (VRTX) delivered a total return of +97.

7%, compared to -57. 4% for European Wax Center, Inc. (EWCZ). Over 10 years, the gap is even starker: VRTX returned +388. 1% versus EWCZ's -57. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Biogen Inc.

(BIIB) is the lower-risk stock at 0. 60β versus FAT Brands Inc. 's 1. 54β — meaning FAT is approximately 156% more volatile than BIIB relative to the S&P 500. On balance sheet safety, Regeneron Pharmaceuticals, Inc. (REGN) carries a lower debt/equity ratio of 9% versus 4% for European Wax Center, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), FAT Brands Inc.

(FAT) is pulling ahead at 23. 4% versus -1. 9% for European Wax Center, Inc. (EWCZ). On earnings-per-share growth, the picture is similar: Vertex Pharmaceuticals Incorporated grew EPS 836. 5% year-over-year, compared to -98. 3% for FAT Brands Inc.. Over a 3-year CAGR, FAT leads at 70. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Vertex Pharmaceuticals Incorporated (VRTX) is the more profitable company, earning 32.

7% net margin versus -32. 0% for FAT Brands Inc. — meaning it keeps 32. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: VRTX leads at 39. 4% versus -8. 8% for FAT. At the gross margin level — before operating expenses — REGN leads at 85. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Regeneron Pharmaceuticals, Inc. (REGN) is the more undervalued stock at a PEG of 2. 43x versus Vertex Pharmaceuticals Incorporated's 2. 69x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, European Wax Center, Inc. (EWCZ) trades at 8. 5x forward P/E versus 22. 2x for Vertex Pharmaceuticals Incorporated — 13. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for VRTX: 30. 1% to $552. 80.

In this comparison, FAT (100.

0% yield), REGN (0. 5% yield), EWCZ (0. 3% yield) pay a dividend. BIIB, VRTX do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Vertex Pharmaceuticals Incorporated (VRTX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

77), +388. 1% 10Y return). Both have compounded well over 10 years (VRTX: +388. 1%, EWCZ: -57. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (EWCZ (Consumer Defensive) and REGN (Healthcare) and BIIB (Healthcare) and FAT (Consumer Cyclical) and VRTX (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: EWCZ is a small-cap quality compounder stock; REGN is a mid-cap deep-value stock; BIIB is a mid-cap quality compounder stock; FAT is a small-cap high-growth stock; VRTX is a mid-cap quality compounder stock. FAT pays a dividend while EWCZ, REGN, BIIB, VRTX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.